MATTR
18.6.2021 07:02:10 CEST | Business Wire | Press release
MATTR, a provider of verifiable data and digital trust solutions, today announced the availability of the MATTR VII platform on Auth0 Marketplace , a catalog of trusted technology integrations to extend the functionality of Auth0’s identity management platform.
The MATTR VII platform provides an integrated approach to decentralised identity and data ownership. It decouples a user’s identity from their service providers, delivering significant benefits to users and giving builders and developers all the tools they need to create a whole new universe of decentralized products and applications. MATTR VII is composable and configurable to fit developers’ needs, whether it’s a well-established business with legacy systems or a start-up looking to build the next best thing in digital privacy.
“MATTR is pleased to partner with Auth0, and welcomes Auth0’s recognition that MATTR’s approach to decentralised identity and data ownership can provide a powerful way to extend and enhance investment already made in authentication and identity solutions,” said Claire Barber, CEO at MATTR. “We’re looking forward to seeing the innovation and value that these new tools are used to create.”
“It has been really exciting to work with MATTR on a newly-built partner integration for the Auth0 Marketplace . This best-in-class solution adds an integral layer to our platform that provides our customers with greater choice and flexibility,” said Cassio Sampaio, SVP of Product at Auth0. “After speaking with many customers, we have identified the types of integrations that matter to them, and we are so thrilled to have MATTR as a vetted and valuable vendor in Auth0 Marketplace.”
With MATTR and Auth0, organizations can act as authoritative issuers of verifiable credentials, leveraging their existing Auth0 accounts and OpenID Connect flows to issue portable credentials to employees, customers or partners.
MATTR VII with the OIDC Bridge Extension complements Auth0 Extensible Identity, and the ease in which customers can seamlessly integrate adjacent technologies to facilitate the successful execution of larger projects such as digital transformation, threat detection, compliance, and customer conversion.
All partner integrations are thoroughly vetted and verified for security and functionality by Auth0, and are easily discoverable for customers. Partners can participate in the growing demand for digital identity solutions and increase their visibility as part of the Auth0 Marketplace, and can learn more here: https://auth0.com/partners .
About Auth0
Auth0’s modern approach to identity enables organizations to provide secure access to any application, for any user. The Auth0 platform is a highly customizable identity operating system that is as simple as development teams want and as flexible as they need. Safeguarding billions of login transactions each month, Auth0 delivers convenience, privacy, and security so customers can focus on innovation. For more information, visit https://auth0.com
.
About MATTR
MATTR is building a web of trust, restoring confidence in digital interactions through an integrated approach to decentralised identity and data ownership. The MATTR VII platform provides the building blocks to address the historically difficult challenges of digital security, privacy and data verification. Our products are simple, accessible and easy to use, with pre-built extensions that make it easy to plug the platform into existing application stacks. MATTR is committed to open standards, and works with organisations such as W3C, DIF and OIDF.
For more information visit https://mattr.global or follow @MattrGlobal on Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210617005938/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom